167 related articles for article (PubMed ID: 21757154)
1. Short-term fenofibrate treatment reduces elevated plasma Lp-PLA2 mass and sVCAM-1 levels in a subcohort of hypertriglyceridemic GOLDN participants.
Tsai AK; Steffen BT; Ordovas JM; Straka R; Zhou X; Hanson NQ; Arnett D; Tsai MY
Transl Res; 2011 Aug; 158(2):99-105. PubMed ID: 21757154
[TBL] [Abstract][Full Text] [Related]
2. Fenofibrate reduces lipoprotein associated phospholipase A2 mass and oxidative lipids in hypertriglyceridemic subjects with the metabolic syndrome.
Rosenson RS
Am Heart J; 2008 Mar; 155(3):499.e9-16. PubMed ID: 18294485
[TBL] [Abstract][Full Text] [Related]
3. Intensive lifestyle modification reduces Lp-PLA2 in dyslipidemic HIV/HAART patients.
Wooten JS; Nambi P; Gillard BK; Pownall HJ; Coraza I; Scott LW; Nambi V; Ballantyne CM; Balasubramanyam A
Med Sci Sports Exerc; 2013 Jun; 45(6):1043-50. PubMed ID: 23299761
[TBL] [Abstract][Full Text] [Related]
4. The effect of orlistat and fenofibrate, alone or in combination, on small dense LDL and lipoprotein-associated phospholipase A2 in obese patients with metabolic syndrome.
Filippatos TD; Gazi IF; Liberopoulos EN; Athyros VG; Elisaf MS; Tselepis AD; Kiortsis DN
Atherosclerosis; 2007 Aug; 193(2):428-37. PubMed ID: 16911813
[TBL] [Abstract][Full Text] [Related]
5. Effect of fenofibrate on serum inflammatory markers in patients with high triglyceride values.
Tsimihodimos V; Kostoula A; Kakafika A; Bairaktari E; Tselepis AD; Mikhailidis DP; Elisaf M
J Cardiovasc Pharmacol Ther; 2004 Mar; 9(1):27-33. PubMed ID: 15094966
[TBL] [Abstract][Full Text] [Related]
6. Effects of fenofibrate on plasma oxidized LDL and 8-isoprostane in a sub-cohort of GOLDN participants.
Dong Y; Steffen BT; Cao J; Tsai AK; Ordovas J; Straka R; Zhou X; Kabagambe E; Hanson NQ; Arnett D; Tsai MY
Atherosclerosis; 2011 Feb; 214(2):422-5. PubMed ID: 21159339
[TBL] [Abstract][Full Text] [Related]
7. Effects of fenofibrate on endothelial function and cell adhesion molecules during post-prandial lipemia in hypertriglyceridemia.
Marchesi S; Lupattelli G; Lombardini R; Roscini AR; Siepi D; Vaudo G; Pirro M; Sinzinger H; Schillaci G; Mannarino E
J Clin Pharm Ther; 2003 Oct; 28(5):419-24. PubMed ID: 14632967
[TBL] [Abstract][Full Text] [Related]
8. Simvastatin but not bezafibrate decreases plasma lipoprotein-associated phospholipase A₂ mass in type 2 diabetes mellitus: relevance of high sensitive C-reactive protein, lipoprotein profile and low-density lipoprotein (LDL) electronegativity.
Constantinides A; de Vries R; van Leeuwen JJ; Gautier T; van Pelt LJ; Tselepis AD; Lagrost L; Dullaart RP
Eur J Intern Med; 2012 Oct; 23(7):633-8. PubMed ID: 22902096
[TBL] [Abstract][Full Text] [Related]
9. Differential effect of hypolipidemic drugs on lipoprotein-associated phospholipase A2.
Saougos VG; Tambaki AP; Kalogirou M; Kostapanos M; Gazi IF; Wolfert RL; Elisaf M; Tselepis AD
Arterioscler Thromb Vasc Biol; 2007 Oct; 27(10):2236-43. PubMed ID: 17656665
[TBL] [Abstract][Full Text] [Related]
10. Lipoprotein-associated phospholipase A₂ activity and mass in relation to vascular disease and nonvascular mortality.
Heart Protection Study Collaborative Group
J Intern Med; 2010 Oct; 268(4):348-58. PubMed ID: 21050287
[TBL] [Abstract][Full Text] [Related]
11. Fenofibrate, HDL, and cardiovascular disease in Type-2 diabetes: The DAIS trial.
Tsunoda F; Asztalos IB; Horvath KV; Steiner G; Schaefer EJ; Asztalos BF
Atherosclerosis; 2016 Apr; 247():35-39. PubMed ID: 26854974
[TBL] [Abstract][Full Text] [Related]
12. Effect of micronized fenofibrate on plasma lipoprotein levels and hemostatic parameters of hypertriglyceridemic patients with low levels of high-density lipoprotein cholesterol in the fed and fasted state.
Genest J; Nguyen NH; Theroux P; Davignon J; Cohn JS
J Cardiovasc Pharmacol; 2000 Jan; 35(1):164-72. PubMed ID: 10630748
[TBL] [Abstract][Full Text] [Related]
13. The effect of darapladib on plasma lipoprotein-associated phospholipase A2 activity and cardiovascular biomarkers in patients with stable coronary heart disease or coronary heart disease risk equivalent: the results of a multicenter, randomized, double-blind, placebo-controlled study.
Mohler ER; Ballantyne CM; Davidson MH; Hanefeld M; Ruilope LM; Johnson JL; Zalewski A;
J Am Coll Cardiol; 2008 Apr; 51(17):1632-41. PubMed ID: 18436114
[TBL] [Abstract][Full Text] [Related]
14. Phospholipase A2 enzymes, high-dose atorvastatin, and prediction of ischemic events after acute coronary syndromes.
Ryu SK; Mallat Z; Benessiano J; Tedgui A; Olsson AG; Bao W; Schwartz GG; Tsimikas S;
Circulation; 2012 Feb; 125(6):757-66. PubMed ID: 22230483
[TBL] [Abstract][Full Text] [Related]
15. Increased soluble vascular adhesion molecule-1 concentration is associated with impaired coronary flow reserve in cardiac syndrome X.
Shim BJ; Lee DH; Youn HJ
Heart Vessels; 2014 Nov; 29(6):723-31. PubMed ID: 24173712
[TBL] [Abstract][Full Text] [Related]
16. Relationship of lipoprotein-associated phospholipase A₂ mass and activity with incident vascular events among primary prevention patients allocated to placebo or to statin therapy: an analysis from the JUPITER trial.
Ridker PM; MacFadyen JG; Wolfert RL; Koenig W
Clin Chem; 2012 May; 58(5):877-86. PubMed ID: 22419750
[TBL] [Abstract][Full Text] [Related]
17. The reduction of inflammatory biomarkers by statin, fibrate, and combination therapy among diabetic patients with mixed dyslipidemia: the DIACOR (Diabetes and Combined Lipid Therapy Regimen) study.
Muhlestein JB; May HT; Jensen JR; Horne BD; Lanman RB; Lavasani F; Wolfert RL; Pearson RR; Yannicelli HD; Anderson JL
J Am Coll Cardiol; 2006 Jul; 48(2):396-401. PubMed ID: 16843192
[TBL] [Abstract][Full Text] [Related]
18. Distribution and correlates of lipoprotein-associated phospholipase A2 in an elderly cohort: the Cardiovascular Health Study.
Furberg CD; Nelson JJ; Solomon C; Cushman M; Jenny NS; Psaty BM
J Am Geriatr Soc; 2008 May; 56(5):792-9. PubMed ID: 18363676
[TBL] [Abstract][Full Text] [Related]
19. The effect of marine n-3 fatty acids in different doses on plasma concentrations of Lp-PLA2 in healthy adults.
Pedersen MW; Koenig W; Christensen JH; Schmidt EB
Eur J Nutr; 2009 Feb; 48(1):1-5. PubMed ID: 19030909
[TBL] [Abstract][Full Text] [Related]
20. Lipoprotein-associated phospholipase A(2) (Lp-PLA(2)) in acute coronary syndrome: relationship with low-density lipoprotein cholesterol.
Jabor B; Choi H; Ruel I; Hafiane A; Mourad W; Genest J
Can J Cardiol; 2013 Dec; 29(12):1679-86. PubMed ID: 24267807
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
